報價延遲最少15分鐘:2026/04/26 00:53 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.98/-57.51
|
|
企業價值
1.53B
|
| 資產負債 |
|
每股賬面淨值
-2.92
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226. |
